• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.

作者信息

Greco Antonio, Buccheri Sergio, D'Arrigo Paolo, Calderone Dario, Agnello Federica, Monte Marco, Milluzzo Rocco Paolo, Franchina Antonio Gabriele, Ingala Salvatore, Capodanno Davide

机构信息

Division of Cardiology, C.A.S.T., Azienda Ospedaliero-Universitaria 'Policlinico-San Marco', University of Catania, Catania, Italy.

Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):335-337. doi: 10.1093/ehjcvp/pvaa074.

DOI:10.1093/ehjcvp/pvaa074
PMID:32671399
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7454531/
Abstract
摘要

相似文献

1
Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.肾素-血管紧张素-醛固酮系统阻滞剂在新型冠状病毒肺炎患者中的疗效：一项系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):335-337. doi: 10.1093/ehjcvp/pvaa074.
2
The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.肾素-血管紧张素-醛固酮系统：在 COVID-19 中的发病机制中的作用及潜在治疗靶点。
Pharmacol Res Perspect. 2020 Aug;8(4):e00623. doi: 10.1002/prp2.623.
3
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
4
Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎患者的预后：一项病例系列研究。
Hypertension. 2020 Aug;76(2):e10-e12. doi: 10.1161/HYPERTENSIONAHA.120.15312. Epub 2020 May 8.
5
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
6
Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.血管紧张素转换酶2（ACE2）受体及血管紧张素转换酶抑制剂（ACEIs）/血管紧张素Ⅱ受体阻滞剂（ARBs）与新型冠状病毒肺炎（COVID-19）疾病严重程度的关联
Drug Discov Ther. 2020;14(4):161-170. doi: 10.5582/ddt.2020.03064.
7
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.SARS-CoV-2 利用血管紧张素转换酶 2 进入细胞进行复制的机制概述：与肾素-血管紧张素系统相关的可能治疗选择。
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):317-325. doi: 10.1093/ehjcvp/pvaa053.
8
COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.新型冠状病毒肺炎与相对血管紧张素转换酶2缺乏：在疾病严重程度和治疗反应中的作用
Open Heart. 2020 Jun;7(1). doi: 10.1136/openhrt-2020-001302.
9
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.肾素血管紧张素系统抑制剂对2019冠状病毒病（COVID-19）患者死亡率的影响：一项系统评价和荟萃分析。
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):983-990. doi: 10.1016/j.dsx.2020.06.047. Epub 2020 Jun 27.
10
[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].[年龄、合并症及肾素-血管紧张素-醛固酮系统在新型冠状病毒肺炎中的作用。血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的影响]
Kardiologiia. 2020 Apr 8;60(4):4-9. doi: 10.18087/cardio.2020.4.n1122.

引用本文的文献

1
Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity.血管紧张素转化酶抑制剂和血管紧张素受体拮抗剂在新型冠状病毒肺炎治疗中的作用
Rev Port Cardiol. 2023 Apr;42(4):373-383. doi: 10.1016/j.repc.2022.02.014. Epub 2023 Mar 7.
2
Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.连续使用肾素-血管紧张素系统抑制剂对因 2019 年冠状病毒病住院患者死亡率的影响：系统评价、荟萃分析和荟萃回归分析。
BMC Infect Dis. 2023 Jan 24;23(1):53. doi: 10.1186/s12879-023-07994-7.
3
An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与新型冠状病毒肺炎不良结局相关性的网状Meta 分析和系统评价
Eur J Clin Invest. 2023 Feb;53(2):e13888. doi: 10.1111/eci.13888. Epub 2022 Oct 19.
4
Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study.门诊使用肾素-血管紧张素-醛固酮系统阻滞剂与 COVID-19 大流行期间急性呼吸道疾病结局的关联：一项队列研究。
BMJ Open. 2022 Jul 6;12(7):e060305. doi: 10.1136/bmjopen-2021-060305.
5
Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.肾素-血管紧张素-醛固酮系统抑制剂与 COVID-19：系统评价和荟萃分析揭示了大量观察性研究中的关键偏倚。
J Am Heart Assoc. 2022 Jun 7;11(11):e025289. doi: 10.1161/JAHA.122.025289. Epub 2022 May 27.
6
Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review.COVID-19期间泌尿外科药物治疗及疫苗接种的药物治疗方法：一项叙述性综述
Ther Adv Urol. 2021 Sep 28;13:17562872211046794. doi: 10.1177/17562872211046794. eCollection 2021 Jan-Dec.
7
Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis.血管紧张素转化酶抑制剂/血管紧张素受体阻滞剂对确诊 COVID-19 患者全因死亡率和其他临床结局影响的系统评价和荟萃分析。
J Clin Hypertens (Greenwich). 2021 Sep;23(9):1651-1663. doi: 10.1111/jch.14329. Epub 2021 Jul 28.
8
SARS-CoV-2 and hypertension.SARS-CoV-2 与高血压。
Physiol Rep. 2021 Jun;9(11):e14800. doi: 10.14814/phy2.14800.
9
Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic.肾素-血管紧张素系统及其调节剂在新冠疫情期间的争议性作用
Front Physiol. 2021 Feb 22;12:624052. doi: 10.3389/fphys.2021.624052. eCollection 2021.
10
Remote monitoring for heart failure management during COVID-19 pandemic.COVID-19大流行期间心力衰竭管理的远程监测
Int J Cardiol Heart Vasc. 2021 Feb;32:100724. doi: 10.1016/j.ijcha.2021.100724. Epub 2021 Jan 28.

本文引用的文献

1
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎关系的Meta分析
Am J Cardiol. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2.
2
Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.评估肾素-血管紧张素-醛固酮系统（RAAS）抑制剂对 COVID-19 结局的影响：一项荟萃分析。
J Infect. 2020 Aug;81(2):276-281. doi: 10.1016/j.jinf.2020.05.052. Epub 2020 May 28.
3
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.美国心力衰竭学会/美国心脏病学会/美国心脏协会联合声明回应关于在2019冠状病毒病中使用肾素-血管紧张素-醛固酮系统拮抗剂的担忧。
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
4
Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎
N Engl J Med. 2020 Jun 18;382(25):2462-2464. doi: 10.1056/NEJMe2012924. Epub 2020 May 1.
5
Potential Effects of Coronaviruses on the Cardiovascular System: A Review.冠状病毒对心血管系统的潜在影响：综述。
JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286.
6
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行：目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
7
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
8
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.